Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
Cardinal Health Chief Financial Officer Aaron E. Alt reported a change in beneficial ownership on 08/12/2025. The Form 4 shows an acquisition of 67,448 common shares through performance share units that are stated to settle on August 15, 2025, with a reported transaction price of $0 (reflecting award settlement). Following the reported transaction, the filing lists total beneficial ownership of 102,396 shares. The filing was executed by an attorney-in-fact and contains an explanatory remark that the shares reflect performance share units.
Cardinal Health Chief Financial Officer Aaron E. Alt reported a change in beneficial ownership on 08/12/2025. The Form 4 shows an acquisition of 67,448 common shares through performance share units that are stated to settle on August 15, 2025, with a reported transaction price of $0 (reflecting award settlement). Following the reported transaction, the filing lists total beneficial ownership of 102,396 shares. The filing was executed by an attorney-in-fact and contains an explanatory remark that the shares reflect performance share units.
Cardinal Health filed a Form S-3 shelf prospectus dated August 12, 2025 that permits the company to offer, from time to time, Class A common shares, preferred shares, unsecured debt securities, units or any combination of these securities; prospectus supplements will specify terms for each offering. The company is a well-known seasoned issuer and its common shares trade on the NYSE under the symbol CAH.
The Articles authorize up to 750 million common shares; as of June 30, 2025 approximately 271 million common shares were issued and about 32 million were held in treasury. The Articles also authorize 5 million Class B common shares (none outstanding) and 500,000 preferred non-voting shares (none outstanding).
The prospectus incorporates Cardinal Health’s Annual Report for the fiscal year ended June 30, 2025 and enumerates material risks including opioid-related litigation and a U.S. DOJ review of anti-diversion practices, the Company’s Corporate Integrity Agreement, EtO sterilization regulatory and litigation risks, high sales concentration with CVS Health, supply chain and tariff uncertainties, and commodity cost pressures. Net proceeds are intended for general corporate purposes.
Cardinal Health filed a Form S-3 shelf prospectus dated August 12, 2025 that permits the company to offer, from time to time, Class A common shares, preferred shares, unsecured debt securities, units or any combination of these securities; prospectus supplements will specify terms for each offering. The company is a well-known seasoned issuer and its common shares trade on the NYSE under the symbol CAH.
The Articles authorize up to 750 million common shares; as of June 30, 2025 approximately 271 million common shares were issued and about 32 million were held in treasury. The Articles also authorize 5 million Class B common shares (none outstanding) and 500,000 preferred non-voting shares (none outstanding).
The prospectus incorporates Cardinal Health’s Annual Report for the fiscal year ended June 30, 2025 and enumerates material risks including opioid-related litigation and a U.S. DOJ review of anti-diversion practices, the Company’s Corporate Integrity Agreement, EtO sterilization regulatory and litigation risks, high sales concentration with CVS Health, supply chain and tariff uncertainties, and commodity cost pressures. Net proceeds are intended for general corporate purposes.
Cardinal Health reported consolidated revenue of $222.6 billion for fiscal 2025, down 2% from the prior year largely because key Pharma distribution contracts with OptumRx expired (OptumRx accounted for 17% of consolidated revenue in fiscal 2024). Despite lower revenue, GAAP operating earnings rose 83% to $2.3 billion and GAAP diluted EPS increased 87% to $6.45, while non-GAAP operating earnings rose 15% to $2.8 billion and non-GAAP diluted EPS was $8.24, reflecting stronger branded and specialty pharmaceutical contributions and results from newly acquired MSO and at-home businesses.
The company deployed $5.3 billion for acquisitions in fiscal 2025, completed major transactions including a 73% interest in GI Alliance (~$2.8 billion), ADS ($1.1 billion), and ION ($1.1 billion), and recognized higher acquisition-related amortization and costs. Cash and equivalents fell to $3.9 billion, long-term obligations were $8.5 billion, and an opioid litigation accrual totaled $4.9 billion, while interest expense increased to $215 million due to new debt financing.
Cardinal Health reported consolidated revenue of $222.6 billion for fiscal 2025, down 2% from the prior year largely because key Pharma distribution contracts with OptumRx expired (OptumRx accounted for 17% of consolidated revenue in fiscal 2024). Despite lower revenue, GAAP operating earnings rose 83% to $2.3 billion and GAAP diluted EPS increased 87% to $6.45, while non-GAAP operating earnings rose 15% to $2.8 billion and non-GAAP diluted EPS was $8.24, reflecting stronger branded and specialty pharmaceutical contributions and results from newly acquired MSO and at-home businesses.
The company deployed $5.3 billion for acquisitions in fiscal 2025, completed major transactions including a 73% interest in GI Alliance (~$2.8 billion), ADS ($1.1 billion), and ION ($1.1 billion), and recognized higher acquisition-related amortization and costs. Cash and equivalents fell to $3.9 billion, long-term obligations were $8.5 billion, and an opioid litigation accrual totaled $4.9 billion, while interest expense increased to $215 million due to new debt financing.
Cardinal Health, Inc. disclosed that it has issued a news release reporting results for the quarter and fiscal year ended June 30, 2025. The company has scheduled a management webcast where the CEO and CFO will discuss those results and provide commentary on the outlook for the fiscal year ending June 30, 2026. The slide presentation and an audio replay will be available on the company’s Investors page.
The filing also reports that The Specialty Alliance, Cardinal Health’s multi-specialty management services organization, has entered into a definitive agreement to acquire Solaris Health. The two news releases are furnished as exhibits to the report.
Cardinal Health, Inc. disclosed that it has issued a news release reporting results for the quarter and fiscal year ended June 30, 2025. The company has scheduled a management webcast where the CEO and CFO will discuss those results and provide commentary on the outlook for the fiscal year ending June 30, 2026. The slide presentation and an audio replay will be available on the company’s Investors page.
The filing also reports that The Specialty Alliance, Cardinal Health’s multi-specialty management services organization, has entered into a definitive agreement to acquire Solaris Health. The two news releases are furnished as exhibits to the report.